Semaglutide (Ozempic, Novo Nordisk, Bagsvrd, Denmark) and tirzepatide (Mounjaro, Eli Lilly and Company, Indianapolis, IN, USA) were used
Energy levels during fasted states often improve noticeably by week 4
With the popularity of GLP-1 agonists ever-increasing and over 150 GLP-1 drug candidates in development [3], the field is continually expanding, most recently into oncology and obesity-related cancers.[4] While most approved GLP-1RAs require subcutaneous injection, substantial work is being undertaken to move toward oral GLP-1 therapies [5], such as Rybelsus which was the first oral GLP-1RA approved by the FDA in 2019
Lillys triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful phase 3 trial
Semaglutide injection improves body mass index (BMI) and overall body weight by regulating blood sugar and encouraging weight reduction
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine , 2021